- Home
- PLCE vs VTGN Comparison
PLCE vs VTGN Comparison
Compare PLCE & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- VTGN
- Stock Information
- Founded
- PLCE 1969
- VTGN 1998
- Country
- PLCE United States
- VTGN United States
- Employees
- PLCE N/A
- VTGN N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- PLCE Consumer Discretionary
- VTGN Health Care
- Exchange
- PLCE Nasdaq
- VTGN Nasdaq
- Market Cap
- PLCE 76.8M
- VTGN 62.9M
- IPO Year
- PLCE 1997
- VTGN N/A
- Fundamental
- Price
- PLCE $5.71
- VTGN $2.24
- Analyst Decision
- PLCE Hold
- VTGN
- Analyst Count
- PLCE 2
- VTGN 0
- Target Price
- PLCE $9.00
- VTGN N/A
- AVG Volume (30 Days)
- PLCE 601.6K
- VTGN 89.0K
- Earning Date
- PLCE 06-11-2025
- VTGN 06-10-2025
- Dividend Yield
- PLCE N/A
- VTGN N/A
- EPS Growth
- PLCE N/A
- VTGN N/A
- EPS
- PLCE N/A
- VTGN N/A
- Revenue
- PLCE $1,386,269,000.00
- VTGN $698,000.00
- Revenue This Year
- PLCE N/A
- VTGN N/A
- Revenue Next Year
- PLCE N/A
- VTGN N/A
- P/E Ratio
- PLCE N/A
- VTGN N/A
- Revenue Growth
- PLCE N/A
- VTGN N/A
- 52 Week Low
- PLCE $4.77
- VTGN $1.90
- 52 Week High
- PLCE $19.74
- VTGN $4.75
- Technical
- Relative Strength Index (RSI)
- PLCE 45.68
- VTGN 46.94
- Support Level
- PLCE $4.81
- VTGN $2.10
- Resistance Level
- PLCE $6.00
- VTGN $2.45
- Average True Range (ATR)
- PLCE 0.48
- VTGN 0.13
- MACD
- PLCE 0.17
- VTGN 0.02
- Stochastic Oscillator
- PLCE 57.32
- VTGN 53.33
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.